Olive AI set out to automate the mountains of repetitive administrative work that bog down hospitals and insurance companies. Founded in 2012 by Sean Lane in Columbus, Ohio, the company built AI-powered bots that handled prior authorizations, eligibility verifications, claims status checks, and other back-office processes that typically require staff to manually log into multiple systems and copy data between them.
At its peak, Olive’s software ran in over 900 hospitals across the United States. The bots worked around the clock, processing tasks that would otherwise take human workers minutes each — and with error rates far below manual entry. The company positioned itself as the “internet of healthcare” and attracted massive venture funding, raising over $900 million at a peak valuation of $4 billion.
The story took a sharp turn in 2023. Despite strong adoption, Olive struggled with profitability and operational challenges that come with scaling enterprise AI. The company made the difficult decision to wind down operations and sell off its business units. Its prior authorization technology went to Humana, the clearinghouse business went to Waystar, and other assets were sold to various acquirers. Olive’s rise and fall became a cautionary tale about the gap between venture hype and sustainable healthcare IT business models. The technology itself wasn’t the problem — execution at scale in a complex, regulated industry proved harder than anyone anticipated.
